TL1A (Control Peptide) (TNFSF15, Tumor Necrosis Factor Ligand Superfamily Member 15)
Catalog No : USB-T8038-05A
367.83€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | TL1A (Control Peptide) (TNFSF15, Tumor Necrosis Factor Ligand Superfamily Member 15) | ||
|---|---|---|---|
| Catalog No | USB-T8038-05A | ||
| Supplier’s Catalog No | T8038-05A | ||
| Supplier | US Biologicals | ||
| Source antigen | |||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | |||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Purified | ||
| Purity | Purified | ||
| Form | Supplied as a liquid in PBS, pH 7.2, 0.1% BSA, 0.02% sodium azide. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Purified | ||
| Description | TL1A, also known as tumor necrosis factor ligand superfamily member 15 (TNFSF15). TL1A acts as a co-stimulator of IFN-gamma secretion through binding to DR3 (death domain receptor 3 or TRAMP) and may play an important role in Th1-mediated diseases such as Crohn’s disease. In cells expressing DR3, TL1A induces NF-kappa-B activation and apoptosis. Decoy receptor 3 (DcR3) is also a receptor for TL1A. DcR3 can apparently neutralise the effect of TL1A, by inhibiting the TL1A-DR3 interaction, thereby inhibiting apoptosis. TL1A is specifically expressed on endothelial cells and is detected on monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon. Location: 14aa near the amino terminus of human TL1A (1). Applications: The peptide is used for blocking the activity of TL1A (NT) antibody. It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37°C. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved